Feature | February 18, 2015

Wearable Monitors Reduce Costs of Arrhythmia Detection Versus Holter Monitors

iRhythm, ZIO Service, arrhythmia detection, wearable, Holter monitors

February 18, 2015 — iRhythm Technologies Inc. announced the study, “Cost Analysis and Clinical Outcomes of Ambulatory Care Monitoring in Medicare Patients,” was published in the Journal of Health Economics and Outcomes Research. The study assessed the costs incurred in the diagnosis, additional monitoring and following clinical events after the initial use of the Holter monitor among Medicare patients with arrhythmia.

Researchers performed a retrospective, longitudinal claims analysis using a 5 percent random sample of Medicare beneficiaries' claims from the Fee-for-Service (FFS) Standard Analytic Files. The analysis was limited to patients with full benefits for one year prior and two years post the index 24- or 48-hour Holter monitor, with no prior arrhythmia or Holter.

The study, which was funded by iRhythm, suggests that the lack of diagnosis or the need for additional testing after the initial use of the Holter monitor resulted in $45 million, or slightly more than $23,000 per patient, in wasted spending by Medicare. When extrapolated over the entire Medicare Fees-for-Service population, the total was more than $900 million over the two-year study period in wasted spending.

“Arrhythmias are difficult to diagnose. A Holter monitor is typically used to record the heart's electrical signals for a 24- or 48-hour period. However, arrhythmias do occur outside that window,” said Judy Lenane, RN, MHA, executive vice president and chief clinical officer of iRhythm Technologies, Inc.

In a separate analysis conducted by an independent third-party research organization, Decision Driver Analytics Inc., preliminary findings showed that initial use of iRhythm’s Zio Service is expected to reduce two-year costs of diagnosing and managing arrhythmia by an average of $5,500 per patient compared to the Holter monitor.

Furthermore, previous studies have shown the Zio Service ruled in or ruled out arrhythmia in an average of three to four weeks compared to only 36 percent of patients obtaining a definitive diagnosis within two years of their initial diagnostic with a Holter monitor. In addition, in patients with arrhythmia, the Zio Service provided immediate diagnosis, eliminating the need for additional diagnostic testing and enabling immediate and appropriate treatment 94 percent of the time.

The Zio Service integrates biosensor technology that captures electrocardiography data for up to 14 days, analytics and medical expertise for improved arrhythmia detection.

For more information: www.irhythmtech.com


Related Content

News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — A programming algorithm, being tested by HonorHealth Research Institute for those patients with new or ...

Home June 20, 2024
Home
Subscribe Now